---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-316841"
form_type: "8-K"
ticker: null
cik: "0001651311"
company_name: "Merus N.V."
filed_at: "2025-12-12T23:59:59+00:00"
generated_at: "2026-05-16T13:21:40.823247+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Merus completes $6.9B acquisition by Genmab at $97.00 per share; 94.2% tendered

## Summary
- Acquisition closed Dec 12, 2025; total consideration ~$6.9B; shareholders received $97.00 per share in cash.
- 94.2% of outstanding shares validly tendered and accepted; subsequent offering period runs through Dec 29, 2025.
- Board changes: Sven Lundberg, Mark Iwicki, Len Kanavy, Paolo Pucci, Victor Sandor, Jason Haddock departed; Jan van de Winkel appointed CEO.
- Executives Lundberg and Silverman cease as officers; gross-up agreements with aggregate cap of $9.3M for certain executives.

## SEC filing metadata
- accession: 0001193125-25-316841
- form_type: 8-K
- cik: 0001651311
- company_name: Merus N.V.
- filed_at: 2025-12-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 2.01, 3.03, 5.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651311/000119312525316841/0001193125-25-316841-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651311/000119312525316841/d29730d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-316841
- JSON: https://secwatch.observer/filing/0001193125-25-316841.json
- Plain text: https://secwatch.observer/filing/0001193125-25-316841.txt

## Source-grounded claims
- claim_id: a1da49a4f201ed7873e05a2ecc6b7feca13e13ee
  claim: Merus N.V. underwent a change of control involving Genmab A/S and Genmab Holding II B.V. for $97.00 per Common Share in cash (closed 2025-12-12).
  evidence_excerpt: of Parent (“Purchaser”), to purchase all of the issued and outstanding common shares, nominal value €0.09 per share, of the Company (the “Common Shares”), in exchange for $97.00 per Common Share in cash (the “Offer Consideration”), without interest and subject to any applicable tax withholding, upon the terms and subject to the conditions set forth in the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651311/000119312525316841/0001193125-25-316841-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.